FI108539B - Parannettu menetelmä (4R-cis)-1,1-dimetyylietyyli-6-syanometyyli-2,2-dimetyyli-1,3-dioksaani-4-asetaatin syntetisoimiseksi - Google Patents

Parannettu menetelmä (4R-cis)-1,1-dimetyylietyyli-6-syanometyyli-2,2-dimetyyli-1,3-dioksaani-4-asetaatin syntetisoimiseksi Download PDF

Info

Publication number
FI108539B
FI108539B FI931680A FI931680A FI108539B FI 108539 B FI108539 B FI 108539B FI 931680 A FI931680 A FI 931680A FI 931680 A FI931680 A FI 931680A FI 108539 B FI108539 B FI 108539B
Authority
FI
Finland
Prior art keywords
formula
dimethyl
acetate
cis
compound
Prior art date
Application number
FI931680A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI931680L (fi
FI931680A0 (fi
Inventor
Donald Eugene Butler
Alan Millar
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of FI931680L publication Critical patent/FI931680L/fi
Publication of FI931680A0 publication Critical patent/FI931680A0/fi
Application granted granted Critical
Publication of FI108539B publication Critical patent/FI108539B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
FI931680A 1990-10-17 1993-04-14 Parannettu menetelmä (4R-cis)-1,1-dimetyylietyyli-6-syanometyyli-2,2-dimetyyli-1,3-dioksaani-4-asetaatin syntetisoimiseksi FI108539B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59952190 1990-10-17
US07/599,521 US5103024A (en) 1990-10-17 1990-10-17 Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US9106697 1991-09-11
PCT/US1991/006697 WO1992006968A1 (en) 1990-10-17 1991-09-11 Process for the synthesis of (4r-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Publications (3)

Publication Number Publication Date
FI931680L FI931680L (fi) 1993-04-14
FI931680A0 FI931680A0 (fi) 1993-04-14
FI108539B true FI108539B (fi) 2002-02-15

Family

ID=24399962

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931680A FI108539B (fi) 1990-10-17 1993-04-14 Parannettu menetelmä (4R-cis)-1,1-dimetyylietyyli-6-syanometyyli-2,2-dimetyyli-1,3-dioksaani-4-asetaatin syntetisoimiseksi

Country Status (20)

Country Link
US (1) US5103024A (cs)
EP (1) EP0553213B1 (cs)
JP (1) JP3105923B2 (cs)
KR (1) KR0166385B1 (cs)
AT (1) ATE118772T1 (cs)
AU (1) AU646311B2 (cs)
CA (1) CA2092997C (cs)
CZ (5) CZ283003B6 (cs)
DE (1) DE69107622T2 (cs)
DK (1) DK0553213T3 (cs)
ES (1) ES2070519T3 (cs)
FI (1) FI108539B (cs)
HK (1) HK1005026A1 (cs)
HU (2) HU219237B (cs)
IE (1) IE62940B1 (cs)
NO (1) NO301588B1 (cs)
PT (1) PT99244B (cs)
RU (1) RU2067580C1 (cs)
SK (5) SK280938B6 (cs)
WO (1) WO1992006968A1 (cs)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
ES2207202T3 (es) * 1998-04-30 2004-05-16 Kaneka Corporation Procedimiento para producir derivados de acido 6-cianometil-1, 3-dioxano-4-acetico.
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
IN191236B (cs) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
ATE320415T1 (de) 1999-12-17 2006-04-15 Pfizer Science & Tech Ltd Verfahren zur herstellung von kristallin atorvastin kalcium
DE60024133T2 (de) 1999-12-17 2006-08-03 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US20040014195A1 (en) * 1999-12-29 2004-01-22 Diversa Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
EP1728785A1 (en) 2001-01-09 2006-12-06 Warner-Lambert Company LLC 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
HRP20031039A2 (en) 2001-06-29 2005-10-31 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)^-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl^-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
GB0116212D0 (en) * 2001-07-03 2001-08-29 Avecia Ltd Process
HRP20040077A2 (en) 2001-07-30 2004-06-30 Reddys Lab Ltd Dr Crystalline forms vi and vii of atorvastatin-calcium
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
WO2003018547A2 (en) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
WO2003106415A2 (en) * 2002-06-13 2003-12-24 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
EP1375493A1 (en) * 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
EP1534704B1 (en) * 2002-08-06 2007-08-01 Warner-Lambert Company LLC Process for preparing 5-(4-fluorophenyl)-1-¬2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl|-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
EP1562583A1 (en) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
KR100529703B1 (ko) * 2002-09-23 2005-11-17 임광민 키랄 중간체의 제조방법 및 그를 이용한 아토바스타틴의제조방법
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
RS20050760A (sr) * 2003-04-14 2008-04-04 Warner-Lambert Company Llc., Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248957A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
GB0317393D0 (en) * 2003-07-25 2003-08-27 Avecia Ltd Process and compounds
EP2522656A3 (en) 2003-07-25 2013-03-20 Redx Pharma Limited Process and Intermediate Compounds Useful in the Preparation of Statins, Particularly Atorvastatin
AU2004272365A1 (en) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Crystalline forms of `R-(R*,R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
PL1727795T3 (pl) 2004-03-17 2012-06-29 Ranbaxy Laboratories Ltd Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
BRPI0513422A (pt) 2004-07-20 2008-05-06 Warner Lambert Co formas de sais cálcio do ácido (r-(r*))-2-(4- fluorfenil)-(beta), (sigma)-diidróxi-5-(1-metiletil) -3-fenil-4-((fenilamino) carbonil)-1h-pirrol-1-heptanóico (2:1)
EP1784389A4 (en) * 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
EP1814541A4 (en) 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
CA2621507A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
EP1922315B1 (en) * 2005-09-09 2009-05-27 Pfizer Science and Technology Ireland Limited Preparation of an atorvastatin intermediate
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
WO2007057755A1 (en) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
EP2115153B1 (en) 2007-03-01 2013-06-05 BP Corporation North America Inc. Nitrilases, nucleic acids encoding them and methods for making and using them
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
WO2012032035A1 (en) 2010-09-09 2012-03-15 Dsm Sinochem Pharmaceuticals Netherlands B.V. Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
WO2016056031A1 (en) 2014-10-08 2016-04-14 Council Of Scientific & Industrial Research Novel diol compounds synthesis and its use for formal synthesis of (2r, 3 s)-3-hydroxypipecolic acid
CN106008251A (zh) * 2016-05-19 2016-10-12 河南豫辰药业股份有限公司 一种2-苯甲撑-3-氧代-4-甲基-n-苯基戊酰胺的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5093363A (en) * 1989-08-22 1992-03-03 Shionogi & Co., Ltd. 2,4,6-substituted phenol derivatives
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte

Also Published As

Publication number Publication date
HU9701183D0 (en) 1997-09-29
PT99244A (pt) 1992-09-30
NO301588B1 (no) 1997-11-17
DE69107622D1 (de) 1995-03-30
WO1992006968A1 (en) 1992-04-30
CZ209495A3 (en) 1997-12-17
ES2070519T3 (es) 1995-06-01
CZ61493A3 (en) 1994-02-16
HU219237B (en) 2001-03-28
IE913629A1 (en) 1992-04-22
SK280942B6 (sk) 2000-09-12
EP0553213A1 (en) 1993-08-04
SK280941B6 (sk) 2000-09-12
AU8848091A (en) 1992-05-20
HK1005026A1 (en) 1998-12-18
SK33993A3 (en) 1993-10-06
KR0166385B1 (en) 1999-01-15
DE69107622T2 (de) 1995-07-06
JP3105923B2 (ja) 2000-11-06
IE62940B1 (en) 1995-03-08
HU9301122D0 (en) 1993-08-30
CZ282994B6 (cs) 1997-12-17
FI931680L (fi) 1993-04-14
CZ282992B6 (cs) 1997-12-17
RU2067580C1 (ru) 1996-10-10
AU646311B2 (en) 1994-02-17
CA2092997C (en) 2002-05-14
HU213731B (en) 1997-09-29
JPH06502162A (ja) 1994-03-10
DK0553213T3 (da) 1995-07-17
FI931680A0 (fi) 1993-04-14
CZ283003B6 (cs) 1997-12-17
CZ282922B6 (cs) 1997-11-12
CZ124797A3 (en) 1997-12-17
NO931421D0 (no) 1993-04-16
SK280939B6 (sk) 2000-09-12
CZ124697A3 (en) 1997-12-17
EP0553213B1 (en) 1995-02-22
PT99244B (pt) 1999-04-30
CA2092997A1 (en) 1992-04-18
ATE118772T1 (de) 1995-03-15
US5103024A (en) 1992-04-07
SK280940B6 (sk) 2000-09-12
SK280938B6 (sk) 2000-09-12
CZ124597A3 (en) 1997-12-17
KR930702328A (ko) 1993-09-08
CZ282993B6 (cs) 1997-12-17
HUT64049A (en) 1993-11-29
NO931421L (no) 1993-06-16

Similar Documents

Publication Publication Date Title
FI108539B (fi) Parannettu menetelmä (4R-cis)-1,1-dimetyylietyyli-6-syanometyyli-2,2-dimetyyli-1,3-dioksaani-4-asetaatin syntetisoimiseksi
US5248793A (en) Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
HK1005026B (en) Process for the synthesis of (4r-cis)-1, 1-dimethylethyl-6-cyanomethyl-2, 2-dimethyl-1, 3-dioxane-4-acetate
JP3241723B2 (ja) (5r)−1,1−ジメチルエチル6−シアノ−5−オキソ−ヘキサノエートの改良合成法
EP0330172B1 (en) Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5385929A (en) [(Hydroxyphenylamino) carbonyl] pyrroles
US5280126A (en) Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CZ285554B6 (cs) Způsob výroby trans-6-[2-(substituovaný pyrrol-1-yl)alkyl]-pyran-2-onu
AU3349689A (en) Improved process for trans-6-(2-(substituted-pyrrol-1-yl) alkyl)pyran-2-one inhibitors of cholesterol synthesis
NO177423B (no) Forbedret fremgangsmåte for fremstilling av trans-6-[2-(substituert-pyrrol-yl)alkylÅpyran-2-on-inhibitorer for kolesterolsyntese